Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 252

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 252
---
.

We cannot guarantee that
in the future our reporting will always be timely. If we are unable to satisfy SEC filing deadlines or otherwise provide disclosures of
material information on a timely basis, stockholders and potential investors in our Common Stock may have incomplete information about
our business and results of operations, which may impact their ability to make an informed investment decision, result in a reduction
in the trading price, trading volume or analyst coverage of our Common Stock or expose us to potential liability.

We could be subject to securities class
action litigation.

In the past, securities class
action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially
relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. If we face such
litigation, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business.

Any such negative outcome
could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our business practices. Defending
against litigation is costly and time-consuming, and could divert management’s attention and our resources. Furthermore, during
the course of litigation, there could be negative public announcements of the results of hearings, motions or other interim proceedings
or developments, which could have a negative effect on the market price of our Common Stock.

Our failure to meet the continued listing
requirements of Nasdaq could result in a delisting of our securities.

On July 19, 2024, we received
a letter (the “Bid Price Requirement Letter”) from the staff at Nasdaq notifying us that, for the 30 consecutive trading days
prior to the date of the Bid Price Requirement Letter, the closing bid price for the Common Stock has been below the minimum $1.00 per
share required for continued listing on Nasdaq set forth in Nasdaq Listing Rule 450(a)(1), which is required for continued listing of
the Common Stock on Nasdaq (the “Bid Price Requirement”). On October 23, 2024, the trading price for our Common Stock closed
under $0.10 and was the tenth consecutive trading day to do so.

On October 24, 2024, we received a letter from the staff at Nasdaq
notifying us that, because our Common Stock had a closing bid price of $0.10 or less for ten consecutive trading days, it was no longer
eligible to rely upon the 180-day cure